Solicitações de Artigos Científicos

Este formulário tem como objetivo auxiliar profissionais de saúde no Brasil a solicitar informações cientificamente embasadas sobre os estudos da AstraZeneca e inovações científicas em doenças raras. Além disso, permite encaminhar perguntas e solicitar contato com o time de Informações Médicas para suporte científico, em formato de autoatendimento.

Para solicitar os materiais científicos, é necessário informar o nome completo, número do conselho de classe e e-mail para recebimento, além de selecionar os estudos desejados e clicar em “Enviar” ao final.

Ao navegar e fazer uma solicitação, confirmo que minha ação é espontânea.

*Obrigatório

Nome completo*

CRM/CRF/CRB e/ou outros conselhos de classe*

E-mail*

Lista de estudos

HPN Hemoglobinúria Paroxística Noturna

Fattizzo B et al. Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice. Blood. 2025 Jul 24;146(4):411-421. Kulasekararaj A et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2025 Jan;104(1):81-94. Goldschimidt V et al. Clinical characteristics and management of paroxysmal nocturnal haemoglobinuria in Latin America: a narrative review. Annals of Hematology, 2024. Int J Lab Hematol. 2024 May:46 Suppl 1:43-54. doi: 10.1111/ijlh.14281. Epub 2024 Apr 15. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy Francesco Versino 1 2, Bruno Fattizzo 1 2 Affiliations Expand PMID: 38622956 DOI: 10.1111/ijlh.14281.

SHUa Síndrome Hemolítico-Urêmica Atípica

Maria Helena Vaisbich et al. Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN). Braz. J. Nephrol. 2025, 47(2):e20240087. Schaefer F et al. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. Kidney Int Rep. 2024 Jun 20;9(9):2648-2656. Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester RN, Bagga A, Ter Heine R, Johnson S, Licht C, Ma ALT, Noris M, Praga M, Rondeau E, Sinha A, Smith RJH, Sheerin NS, Trimarchi H, Wetzels JFM, Vivarelli M, Van de Kar NCAJ, Greenbaum LA; Forum Participants. Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum. Kidney Int. 2024 Dec;106(6):1038-1050. DOI: 10.1016/j.kint.2024.09.012. Epub 2024 Oct 10. PMID: 39395628. Griffiths EA et al. Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study. Health Qual Life Outcomes. 2024.

NMOSD Transtorno do Espectro da Neuromielite Óptica

Conrad N et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023 Jun 3;401(10391):1878-1890. Alonso R et al. Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND/UCLA methodology. Mult Scler Relat Disord. 2025 Feb;94:106244. Fam S, Parks B, Allen K et al. Meningococcal infections in eculizumab- or ravulizumab-treated patients: a clinical and real-world pharmacovigilance update across indications, including neuromyelitis optica spectrum disorder. Alexion, AstraZeneca Rare Disease, Boston, MA. *Presenting author. Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data DOI: 10.1007/s00415-024-12698-2.

MGg Miastenia Gravis Generalizada

Vu TH et al. Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. Eur J Neurol. 2025 Apr;32(4):e70158. Khani-Habibabadi F et al. Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis Patients. Disponível em: https://doi.org/10.1101/2024.08.28.24312367. Acessado em 18 de agosto de 2025. Andreas Meisel 1, Francesco Saccà 2, Jennifer Spillane 3, John Vissing 4; MG Collegium Sub‐committee Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol. 2024 Jul;31(7):e16280. DOI: 10.1111/ene.16280. Epub 2024 Mar 24. The impact of myasthenia gravis severity on work and daily activities – DOI: 10.1002/mus.28063.

HPP Hipofosfatasia

Rush E et al. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int. 2024 Jan;35(1):1-10. Michigami T et al. Clinical Practice Guidelines for Hypophosphatasia. Clinical Pediatric Endocrinology. Vol.29 / No.1. January 2020. pp 9–24. Jaswanthi N, Sindhu R, Nimmy P et al. Effect of Asfotase Alfa in the Treatment of Hypophosphatasia- A Systematic Review. J Pharm Bioallied Sci. 2023 Jul;15(Suppl 1):S101-S104.

NF1 Neurofibromatose tipo 1

Chen AP et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025 Jun 21;405(10496):2217-2230. Radtke HB et al. Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care. Pediatric Health, Medicine and Therapeutics. 2023;14:19-32. Azizi AA et al. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neurooncol Pract. 2024 Apr 27;11(5):515-531. Carton C et al. ERN GENTURIS NF1 Tumour Management Guideline Group. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023 Jan 13;56:101818. Han Y et al. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. J Neurol. 2024 May;271(5):2379-2389.

Material destinado exclusivamente a profissionais de saúde prescritores ou dispensadores de medicamentos. BR-44997. Setembro/2025.
© AstraZeneca 2025. Todos os Direitos Reservados. Proibida a reprodução total ou parcial sem a autorização do titular.